Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?

Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity...

Descripción completa

Detalles Bibliográficos
Autores principales: Daliri, Karim, Ljubimov, Alexander V., Hekmatimoghaddam, Seyedhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Stem Cell Research 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741193/
https://www.ncbi.nlm.nih.gov/pubmed/28844129
http://dx.doi.org/10.15283/ijsc17029
_version_ 1783288154962264064
author Daliri, Karim
Ljubimov, Alexander V.
Hekmatimoghaddam, Seyedhossein
author_facet Daliri, Karim
Ljubimov, Alexander V.
Hekmatimoghaddam, Seyedhossein
author_sort Daliri, Karim
collection PubMed
description Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. In this perspective we will thus focus on emerging approaches to glaucoma treatment including stem cells and gene therapy.
format Online
Article
Text
id pubmed-5741193
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society for Stem Cell Research
record_format MEDLINE/PubMed
spelling pubmed-57411932017-12-28 Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now? Daliri, Karim Ljubimov, Alexander V. Hekmatimoghaddam, Seyedhossein Int J Stem Cells Review Article Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. In this perspective we will thus focus on emerging approaches to glaucoma treatment including stem cells and gene therapy. Korean Society for Stem Cell Research 2017-11 /pmc/articles/PMC5741193/ /pubmed/28844129 http://dx.doi.org/10.15283/ijsc17029 Text en Copyright ©2017, Korean Society for Stem Cell Research This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Daliri, Karim
Ljubimov, Alexander V.
Hekmatimoghaddam, Seyedhossein
Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title_full Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title_fullStr Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title_full_unstemmed Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title_short Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?
title_sort glaucoma, stem cells, and gene therapy: where are we now?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741193/
https://www.ncbi.nlm.nih.gov/pubmed/28844129
http://dx.doi.org/10.15283/ijsc17029
work_keys_str_mv AT dalirikarim glaucomastemcellsandgenetherapywherearewenow
AT ljubimovalexanderv glaucomastemcellsandgenetherapywherearewenow
AT hekmatimoghaddamseyedhossein glaucomastemcellsandgenetherapywherearewenow

Ejemplares similares